Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan A Grupp

Showing results (171-180 of 238) with videos related to

Pageof 24
Sort By:
Nature Medicine|January 9, 2024
Unanswered questions following reports of secondary malignancies after CAR-T cell therapyBruce L Levine, Marcelo C Pasquini, John E Connolly, et al.
The New England Journal of Medicine|October 16, 2014
Chimeric antigen receptor T cells for sustained remissions in leukemiaShannon L Maude, Noelle Frey, Pamela A Shaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2025
D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung CancerAnna Maria Giudice, Stephanie Matlaga, Sydney L Roth, et al.
Blood Advances|June 24, 2025
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registrySamuel John, Kevin J Curran, Erin M Hall, et al.
Blood|November 9, 2022
Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapyHaley Newman, Yimei Li, Hongyan Liu, et al.
The New England Journal of Medicine|June 11, 2026
Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell DiseaseHaydar Frangoul, Josu de la Fuente, Yogi Chopra, et al.
Blood|September 8, 2012
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemiaShannon L Maude, Sarah K Tasian, Tiffaney Vincent, et al.
The New England Journal of Medicine|October 1, 2010
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaAlice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic LeukemiaKaren Thudium Mueller, Edward Waldron, Stephan A Grupp, et al.
Nature Reviews. Clinical Oncology|January 26, 2021
Beyond the storm - subacute toxicities and late effects in children receiving CAR T cellsHaneen Shalabi, Juliane Gust, Agne Taraseviciute, et al.
Pageof 24

Showing results (171-180 of 238) with videos related to

Sort By:
Pageof 24
Nature Medicine|January 9, 2024
Unanswered questions following reports of secondary malignancies after CAR-T cell therapyBruce L Levine, Marcelo C Pasquini, John E Connolly, et al.
The New England Journal of Medicine|October 16, 2014
Chimeric antigen receptor T cells for sustained remissions in leukemiaShannon L Maude, Noelle Frey, Pamela A Shaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2025
D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung CancerAnna Maria Giudice, Stephanie Matlaga, Sydney L Roth, et al.
Blood Advances|June 24, 2025
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registrySamuel John, Kevin J Curran, Erin M Hall, et al.
Blood|November 9, 2022
Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapyHaley Newman, Yimei Li, Hongyan Liu, et al.
The New England Journal of Medicine|June 11, 2026
Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell DiseaseHaydar Frangoul, Josu de la Fuente, Yogi Chopra, et al.
Blood|September 8, 2012
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemiaShannon L Maude, Sarah K Tasian, Tiffaney Vincent, et al.
The New England Journal of Medicine|October 1, 2010
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaAlice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic LeukemiaKaren Thudium Mueller, Edward Waldron, Stephan A Grupp, et al.
Nature Reviews. Clinical Oncology|January 26, 2021
Beyond the storm - subacute toxicities and late effects in children receiving CAR T cellsHaneen Shalabi, Juliane Gust, Agne Taraseviciute, et al.
Pageof 24